Home Healthcare Walgreens Exec: Reimbursement Fashions Have to Catch Up with GLP-1 Demand

Walgreens Exec: Reimbursement Fashions Have to Catch Up with GLP-1 Demand

Walgreens Exec: Reimbursement Fashions Have to Catch Up with GLP-1 Demand


Exercise within the GLP-1 remedy house is constant to warmth up. On Wednesday, the FDA accredited Eli Lilly’s Zepbound as a remedy for weight reduction administration, which suggests Novo Nordisk‘s blockbuster drug Wegovy has a brand new rival. Lilly’s new drug is identical as its sort 2 diabetes remedy Mounjaro, however it is going to now be marketed beneath the brand new model identify Zepbound.

There may be “an unlimited quantity of demand” for these injectable weight reduction medication, identified John Driscoll, president of U.S. healthcare at Walgreens Boots Alliance, throughout a Wednesday session on the Reuters Complete Well being convention in Chicago. 

“Weight problems is an actual disaster, however in some methods, it’s actually unaddressed and unaddressable. These medication seem to have a cloth influence and, as greatest we all know, a low threat profile, though about 25-30% of individuals do have some type of modest discomfort,” he remarked.

In Driscoll’s view, GLP-1 medicines “are going to profoundly change the best way individuals expertise healthcare.” He added that each on- and off-label use for these medication has grown much more rapidly than individuals anticipated it will on the time they had been accredited. 

Over time, Driscoll believes that GLP-1 medication will “simply change into a part of the material” of power situation administration and the general healthcare system.

“I feel that is most likely nice for power care, though we do have to determine a reimbursement mannequin that accurately compensates pharmacists and others to manage — as a result of that reimbursement hasn’t caught up with the demand,” he declared.

The healthcare business ought to provide you with an applicable reimbursement mannequin for these medication sooner reasonably than later, given the quantity of enthusiasm surrounding GLP-1 medication, Driscoll added. Zepbound’s new approval marks additional enlargement of GLP-1 medication into the burden loss administration house, and he doesn’t see this development slowing down “anytime within the close to future.”

He additionally predicted that an increasing number of pharmaceutical firms will attempt to convey these kinds of merchandise to the market. There may be some huge cash to be made — Eli Lilly’s Mounjaro was solely accredited final 12 months, however has already claimed its spot because the drugmaker’s second-largest vendor, producing greater than $2.9 billion in income for the 12 months up to now. Ozempic has generated about $9.4 billion this 12 months, and Wegovy gross sales complete about $3 billion — each medication are bought by Novo Nordisk.

Like many different healthcare leaders, Driscoll is ready to see how lengthy it is going to take for a generic to enter the market, however he mentioned he doesn’t foresee that occuring anytime quickly.

The healthcare business is “simply on the cusp” of understanding GLP-1 medication’ scope of purposes, Driscoll additionally identified. He mentioned that these medicines may have the ability to deal with dependancy and cardiovascular circumstances — and that “massive scale research are actually promising in these areas.”

Photograph: Reuters Occasions



Please enter your comment!
Please enter your name here